Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Tamoxifen: a personal retrospective.

V C Jordan1

  • 1Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL 60611-3008, USA. vcjordan@northwestern.edu

The Lancet. Oncology
|March 22, 2002
PubMed
Summary

Tamoxifen is a pioneering breast cancer medicine that also serves as a selective oestrogen receptor modulator. This drug class offers benefits beyond cancer treatment, impacting bone health and cholesterol levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.

British journal of cancer·2016
Same author

Stable transfection of protein kinase C alpha cDNA in hormone-dependent breast cancer cell lines.

British journal of cancer·2016
Same author

Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol.

British journal of pharmacology·2014
Same author

Delayed triggering of oestrogen induced apoptosis that contrasts with rapid paclitaxel-induced breast cancer cell death.

British journal of cancer·2014
Same author

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Clinical pharmacology and therapeutics·2013
Same author

Molecular mechanism of action of bisphenol and bisphenol A mediated by oestrogen receptor alpha in growth and apoptosis of breast cancer cells.

British journal of pharmacology·2013

Area of Science:

  • Oncology
  • Pharmacology
  • Endocrinology

Background:

  • Tamoxifen, initially an anti-estrogen and antifertility agent, is now a key breast cancer treatment.
  • Its efficacy stems from successful laboratory research and clinical trials.
  • The drug's mechanism extends beyond anti-estrogen effects, influencing other physiological processes.

Observation:

  • Selective estrogen receptor modulation (SERM) concept emerged in the 1980s.
  • Non-steroidal anti-estrogens exhibit estrogen-like effects on bone and cholesterol.
  • These compounds selectively block estrogen action in breast and uterine tissues.

Findings:

  • Tamoxifen's success paved the way for developing SERMs.
  • Raloxifene, a SERM, is used for osteoporosis prevention.
  • Raloxifene is under investigation for breast cancer prevention.

Implications:

  • SERMs offer a targeted approach to hormone-related conditions.
  • Tamoxifen and related compounds represent a significant advancement in personalized medicine.
  • Further research into SERMs could yield novel therapeutic strategies for various diseases.

Related Experiment Videos